Femasys Inc. announced a 40.8% sales increase in 2025 to $2.29 million, driven by FemBloc sales, while reducing R&D expenses. The company initiated patient enrollment in the pivotal FINALE trial for FDA approval of FemBloc, a non-surgical permanent birth control. Femasys also secured strategic partnerships and regulatory milestones, including FDA clearance for FemVue and a new CPT code for FemaSeed. With $9.3 million in cash, Femasys expects to fund operations into Q3 2026 as it expands commercialization efforts in fertility and birth control markets.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
